Table 3.
Subgroup analysis and meta-regression of clinical variants correlated with apomorphine-induced rotation and amphetamine-induced rotation.
| Clinical variants | Apomorphine-induced rotation | Amphetamine-induced rotation | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of reports | Pooled estimates (SMD) | 95% conf. Interval | P-value for SMD=0 | I 2 value (%) | P-value for heterogeneity | P-value of interaction | Univariate analysis (Adj R2, P) | No. of reports | Pooled estimates (SMD) | 95% conf. Interval | P-value for SMD=0 | I 2 value (%) | P-value for heterogeneity | P-value of interaction | Univariate analysis (Adj R2, P) | |
| Animal gender | ||||||||||||||||
| Male | 6 | 1.432 | (0.742, 2.121) | <.001 | 53.60% | .056 | .610 | –1.20%, 0.428 | 2 | 2.951 | (1.689, 4.213) | <.001 | 0.00% | .324 | .012 | 47.62%, .102 |
| Female | 3 | 1.083 | (–0.069, 2.226) | .063 | 69.10% | .039 | 6 | 1.104 | (0.389, 1.819) | .002 | 67.50% | .009 | ||||
| NPSCs source species | ||||||||||||||||
| Allogeneic | 5 | 1.148 | (0.629, 1.667) | <.001 | 0.00% | .536 | .810 | –21.00%, 0.957 | 3 | 2.108 | (0.007, 4.210) | .049 | 81.50% | .005 | .459 | –15.76%, .536 |
| Xenogeneic | 6 | 1.274 | (0.402, 2.145) | .004 | 75.90% | .001 | 5 | 1.257 | (0.438, 2.076) | .003 | 71.20% | .008 | ||||
| NPSCs state | ||||||||||||||||
| PC-NSPCs | 8 | 0.874 | (0.398, 1.351) | <.001 | 32.90% | .166 | .043 | 75.90%, 0.058 | 7 | 1.678 | (0.771, 2.603) | <.001 | 76.10% | <.001 | — | –18.08%, .479 |
| PSC-NSPCs | 3 | 1.918 | (1.026, 2.809) | <.001 | 51.60% | .127 | 1 | 0.729 | (–0.103, 1.560) | .086 | NA | NA | ||||
| NPSCs dosage | ||||||||||||||||
| ≤1E6 | 3 | 0.588 | (–0.009, 1.185) | .054 | 0.00% | .743 | .049 | 15.82%, 0.159 | 4 | 0.991 | (0.216, 1.765) | .012 | 66.90% | .028 | .174 | 7.49%, .266 |
| >1E6 | 8 | 1.477 | (0.820, 2.135) | <.001 | 63.30% | .008 | 4 | 2.215 | (0.630, 3.799) | .006 | 76.20% | .006 | ||||
| Administration time | ||||||||||||||||
| ≤2 weeks | 3 | 1.852 | (0.798, 2.907) | .001 | 32.60% | .227 | .187 | 3.63%, 0.233 | 1 | 0.359 | (–0.711, 1.429) | .511 | NA | NA | — | –4.92%, .325 |
| >2 weeks | 8 | 1.047 | (0.476, 1.618) | <.001 | 61.60% | .011 | 7 | 1.703 | (0.845, 2.561) | <.001 | 75.00% | .001 | ||||
| Administration site | ||||||||||||||||
| Striatum | 9 | 1.007 | (0.547, 1.466) | <.001 | 37.40% | .120 | .352 | 34.90%, 0.197 | 7 | 1.325 | (0.562, 2.088) | .001 | 71.60% | .002 | — | 9.05%, .356 |
| Substantia nigra | 2 | 1.884 | (0.094, 3.674) | .039 | 79.70% | .026 | 1 | 2.838 | (1.185, 4.491) | .001 | NA | NA | ||||
| Follow-up period | ||||||||||||||||
| <12 weeks | 5 | 1.25 | (0.312, 2.189) | .009 | 65.50% | .021 | .968 | –20.25%, 0.980 | 4 | 1.573 | (0.297, 2.849) | .016 | 74.70% | .008 | .952 | –26.92%, .982 |
| ≥12 weeks | 7 | 1.227 | (0.579, 1.875) | <.001 | 58.80% | .033 | 4 | 1.523 | (0.387, 2.659) | .009 | 78.50% | .003 | ||||
| Pretreatment behavioral assessment | ||||||||||||||||
| Yes | 8 | 1.439 | (0.745, 2.134) | <.001 | 63.30% | .008 | .119 | 2.96%, 0.276 | 6 | 2.002 | (1.137, 2.868) | <.001 | 63.60% | .017 | <.001 | 50.98%, .060 |
| No | 3 | 0.749 | (0.233, 1.266) | .004 | 0.00% | .439 | 2 | 0.243 | (–0.341, 0.826) | .415 | 0.00% | .800 | ||||
I 2 describes the variation in effect size attributable to heterogeneity. Adj R2 represents the proportion of between-study variance explained.
Abbreviations: APC-NSPC, primary cells-neural stem/progenitor cells; PSC-NSPC, pluripotent stem cell-neural stem/progenitor cells; SMD, standardized mean difference.